Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
about
Antiangiogenic therapy for high-grade gliomaAnti-angiogenic therapy for high grade gliomaRole of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastomaβ1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastomaExciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaRecent advances in the molecular understanding of glioblastomaMalignant gliomas: old and new systemic treatment approachesThe evolving roles and controversies of radiotherapy in the treatment of glioblastomaThe Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic ReviewTherapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolveRecurrent Glioblastoma: Where we standConcurrent therapy to enhance radiotherapeutic outcomes in glioblastomaBevacizumab for glioblastomaVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationNonsurgical treatment of recurrent glioblastomaTargeting Aggressive Cancer Stem Cells in GlioblastomaEvolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision MedicineMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateMechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiformeBevacizumab in Japanese patients with malignant glioma: from basic research to clinical trialBiomarkers for glioma immunotherapy: the next generationTwisted tango: brain tumor neurovascular interactionsAn Evidence-Based Review of Alternating Electric Fields Therapy for Malignant GliomasCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsMolecular biology of gliomas: present and future challengesTargeted therapy in advanced bladder cancer: what have we learned?Will kinase inhibitors make it as glioblastoma drugs?Practical management of bevacizumab-related toxicities in glioblastomaAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaContemporary murine models in preclinical astrocytoma drug developmentPaclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Gliomas and the vascular fragility of the blood brain barrierEmerging targeted therapies for glioma.Survival in glioblastoma: a review on the impact of treatment modalities.Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic gliomaPhase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.It is time to include patients with brain tumors in phase I trials in oncology
P2860
Q24193485-44BB4FEA-65A8-4AC0-AB9F-322BBB07E2B5Q24240185-CDFEC9B1-F688-4365-BC48-57874C6675BFQ24295370-84DDB9C2-86BE-4B45-B408-04F7FA9D7609Q24564890-ED81F334-E4FB-4AF7-A408-4080A31A028CQ24632791-5ABAF1B3-27C1-41A8-936E-9BA603FE635DQ24632928-743D4A4E-9D27-49A5-BFC0-E3FCDE92413BQ26744387-AB7EE85F-04D7-45C2-8BA9-9815FE4B17F6Q26746622-FCC4B172-2D76-447C-A786-14ABC8843A75Q26752321-67B7BD12-583E-4324-BE50-6F722266C13BQ26764947-74722CAF-E8AD-4EF9-8E88-688D1E51C40AQ26765042-081A083D-74FC-4FAC-9DA7-CF9010DE1DA1Q26767169-DA183A01-C0F8-4722-98EB-82C69F508558Q26776307-9A6F4EFB-79E3-4D4E-A3F6-81AE94B3C395Q26781833-659404BB-D2E9-43AD-AF8E-59E51AE538D7Q26795560-282976B9-C1B4-4701-8912-3FF80834A620Q26799983-6AFBE174-DEA5-44A4-A160-54616830A499Q26800355-FC5CB422-5915-4842-BD60-7FFF08246CB1Q26822717-E76EB2A8-40C0-41A0-9A28-E5F119E7D848Q26824557-D5051C20-C72A-47AC-B274-2F581C4C1318Q26824777-1FCF4E82-9BCF-4A6C-8585-442196E16589Q26825496-36C27185-8665-439E-96F5-138B22F687CEQ26849613-E37938E6-CFB2-4219-8F1C-C0158B3EDD64Q26852232-42F7D086-B288-4703-92D4-56370532C40AQ26853308-00BDE113-0318-46E7-AC38-A400F0977520Q26853516-7BDDDD97-B8EE-45E0-8A0B-A7F6C51EBB9BQ27001295-5CDCD4B4-2ED9-4B27-AFD9-CAF2A3C231DEQ27009469-A94B7766-EF12-4554-AB7B-B64974BD18B9Q27012684-A64FC9B2-E37D-4E8F-A3A8-1F786105D12CQ27015852-0348E4BD-E7AA-4845-95D8-2090D27E8B60Q27024830-CBDA6DBE-4C5E-4FAF-B53D-04CDCAA07680Q27026937-52F90131-7102-461C-A7EE-2611EBBA2788Q28073057-0399E39B-DBFE-4046-8D85-DB90383C84E7Q28078539-AF48772B-1F0A-49E9-8C88-F4031F9997A5Q28081953-EFF6623B-2AFD-43A5-AA7E-EBF7AE5FA365Q30241853-1470079E-A07E-4792-84F7-3C994E8DE2AAQ30251810-A8F15C31-9F47-40C5-95F6-728A0497BFEBQ30278053-6EE4252B-5198-47D2-BF05-8490A33C7556Q30300986-4B793786-98E5-4474-8E1D-4C6CF13ABE7EQ30301304-A2445AE4-EECC-4737-8D66-0820FD782308Q30359570-3B899AFF-F846-4295-BB19-D3A5142E9590
P2860
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase II trial of single-agent ...... sion in recurrent glioblastoma
@ast
Phase II trial of single-agent ...... sion in recurrent glioblastoma
@en
type
label
Phase II trial of single-agent ...... sion in recurrent glioblastoma
@ast
Phase II trial of single-agent ...... sion in recurrent glioblastoma
@en
prefLabel
Phase II trial of single-agent ...... sion in recurrent glioblastoma
@ast
Phase II trial of single-agent ...... sion in recurrent glioblastoma
@en
P2093
P2860
P356
P1476
Phase II trial of single-agent ...... sion in recurrent glioblastoma
@en
P2093
Cheryl Royce
Howard A Fine
Irene Stroud
Kevin Camphausen
Kraig Moore
Lyndon Kim
Megan Mackey
Nancy Garren
P2860
P304
P356
10.1200/JCO.2008.16.3055
P407
P577
2008-12-29T00:00:00Z